These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 17802710)
1. [Neuromuscular disorders due to adverse effects of antiparkinson agents]. Hattori N Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1614-20. PubMed ID: 17802710 [No Abstract] [Full Text] [Related]
2. Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls. Ahlskog JE Mayo Clin Proc; 2014 Jul; 89(7):997-1003. PubMed ID: 24996235 [TBL] [Abstract][Full Text] [Related]
3. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies. Pahwa R J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613 [TBL] [Abstract][Full Text] [Related]
4. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Young BK; Camicioli R; Ganzini L Drugs Aging; 1997 May; 10(5):367-83. PubMed ID: 9143857 [TBL] [Abstract][Full Text] [Related]
5. Current pharmacotherapeutic treatment options in Parkinson's disease. Rezak M Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328 [TBL] [Abstract][Full Text] [Related]
6. Rasagiline for motor complications in Parkinson's disease. Clarke CE Lancet; 2005 Mar 12-18; 365(9463):914-6. PubMed ID: 15766976 [No Abstract] [Full Text] [Related]
11. Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint. Nyholm D; Askmark H; Aquilonius SM Ann Neurol; 2011 Feb; 69(2):424; author reply 425. PubMed ID: 21387388 [No Abstract] [Full Text] [Related]
12. Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy. Wilson L; Sheehan J; Thorpe M Ir Med J; 2013 Jan; 106(1):24-5. PubMed ID: 23472375 [TBL] [Abstract][Full Text] [Related]
13. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Klos KJ; Bower JH; Josephs KA; Matsumoto JY; Ahlskog JE Parkinsonism Relat Disord; 2005 Sep; 11(6):381-6. PubMed ID: 16109498 [TBL] [Abstract][Full Text] [Related]
14. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996 [TBL] [Abstract][Full Text] [Related]
16. Other pharmacological treatments for motor complications and dyskinesias. Waters C Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104 [TBL] [Abstract][Full Text] [Related]